Duke University Clinical Cardiology Study - 2 - DUCCS-2


Aspirin dosing and thrombolytic therapy for reperfusion in acute MI.


Aspirin dosing and thrombolytic therapy in acute myocardial infarction.

Study Design

Study Design:

Patients Screened: Not given
Patients Enrolled: 162

Patient Populations:

Age > 18 years
ST-segment elevation of ≥ 1 mV in at least 2 contiguous leads or new left bundle branch block

Primary Endpoints:

Clinical reperfusion

Drug/Procedures Used:

APSAC without heparin vs. rTPA with heparin; aspirin 81mg vs 325mg.

Principal Findings:

Patients randomized to APSAC without heparin (n=83) had more bleeding complications than patients given r-tPA with heparin (n=79).

Patients given r-tPA had more rapid clinical reperfusion (resolution of > 50% of ST-segment elevation) than patients randomized to APSAC.

Patients randomized to low-dose aspirin had lower in-hospital mortality compared to the standard-dose aspirin groups.


This head-to-head comparison of APSAC with r-tPA suggested that r-tPA had a more favorable net benefit over APSAC. Although a small study, DUCCS-2 can be considered hypothesis-generating. The ISIS-3 study demonstrated similar findings in a larger population sample.


1. Am J Cardiol 1996;77:791-7.

Clinical Topics: Anticoagulation Management, Arrhythmias and Clinical EP, Dyslipidemia, EP Basic Science, Lipid Metabolism, Novel Agents

Keywords: Thrombolytic Therapy, Myocardial Infarction, Hospital Mortality, Streptokinase, Heparin, Bundle-Branch Block, Anistreplase, Tissue Plasminogen Activator

< Back to Listings